What happened with SINT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
SiNtx Technologies’ main product revenue comes from making spinal-fusion implants and selling them to CTL Medical. These implants are used to treat spine disorders. CTL also acts as the exclusive broker for offering SiNtx’s silicon nitride spinal-device manufacturing services to other developers. The company manufactures in Salt Lake City and also sells ceramic materials, coatings and components for aerospace and other industrial applications.
SiNtx is shifting away from non-core contract manufacturing toward its own silicon nitride medical devices. Its SiNAPTIC foot and ankle wedge system has FDA clearance for reconstructive surgery, and the company is building direct sales and distribution capabilities for it. It has also begun earning revenue from OsseoSculpt, a privately labelled biologic supplied to complement the wedges.
The spinal business depends on CTL and other distribution partners reaching customers. Medical-product acceptance has been limited, and demand depends partly on surgeon adoption and reimbursement for procedures. New devices and uses generally need regulatory clearance or approval before U.S. marketing. SiNtx also needs additional financing to continue operations and develop and commercialize its products.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
SINTX’s results hinge on spinal-device purchases by its principal product customer, CTL Medical, and turning its new foot-and-ankle wedges and complementary biologic into commercial sales.
Xtant Medical competes in the spine and foot-and-ankle markets where SINTX sells fusion implants and is introducing wedges and a complementary biologic. Xtant’s sales of spinal fixation implants and bone-repair biologics through agents and distributors offer a view of competition across both markets.
Carlsmed sells personalized aprevo implants placed between vertebrae to hospitals and ambulatory surgical centers, competing with the silicon nitride fusion devices SINTX makes for CTL. Growth in Carlsmed’s surgeon users and their use of aprevo shows adoption of that competing option.
Alphatec sells spinal implants and biologics for the fusion procedures that also use SINTX’s interbody devices, putting it in competition for those procedures. Surgeon adoption of Alphatec’s procedure-specific products is the development to watch, rather than treating its broad spine revenue as a direct measure of SINTX’s market.
Orthofix competes with SINTX across spinal fusion and reconstructive foot-and-ankle surgery through spinal implants, biologics and limb reconstruction products. Its Global Spine and Global Limb Reconstruction sales are the relevant lines to follow, though both include marketing service fees as well as product sales.
Globus Medical’s musculoskeletal implants and biologics compete with SINTX’s spinal fusion devices and expanding orthopedic range. Its Musculoskeletal Solutions business is the closer comparison, rather than the imaging, navigation and surgical robots in Enabling Technologies.
Stryker’s orthopedic products compete with SINTX’s silicon nitride implants for surgeon adoption and hospital purchases. Watch Stryker’s Orthopaedics sales rather than its larger MedSurg and Neurotechnology business for the more relevant competitive picture.
Zimmer Biomet sells orthopedic reconstruction and extremity implants that offer alternatives to SINTX’s silicon nitride medical devices. Its new and improved orthopedic products are worth watching because it identifies technology, quality and pricing among the main grounds of competition.
Medtronic sells orthopedic devices that SINTX identifies as competitors to its silicon nitride medical products. For this tie, watch Medtronic’s competing device introductions and improvements, not its insulin pumps or glucose-monitoring business.
Smith+Nephew competes with SINTX’s silicon nitride medical products through orthopedic technologies backed by established sales networks and surgeon relationships. Its clinical evidence and healthcare-system adoption matter because stronger evidence or broader adoption of alternatives could limit SINTX’s market share.
Xtant Medical Holdings, Inc. earningsXTNT
Xtant Medical’s report will show demand for spinal fixation implants and bone-repair biologics, offering a read on the spine and foot-and-ankle markets SINTX is entering.
Look at sales of Xtant Medical’s spinal fixation implants and bone-repair biologics, which it sells through agents and distributors. Growth in both would indicate demand in related surgical markets, but would not establish adoption of SINTX’s silicon-nitride products. Weakness would point to a harder market backdrop for SINTX as it expands in spine and foot-and-ankle care.
SiNtx Technologies, Inc. earningsThis company
SINTX’s report will show whether sales of its own medical products are beginning to replace the low-margin manufacturing revenue it chose to leave behind.
Separate product revenue from grant and contract revenue, then compare product revenue with gross profit, which SINTX defines as product revenue relative to cost of revenue. Rising product revenue with improving gross profit—especially if the foot-and-ankle wedge system contributes sales—would show commercialization is taking hold. Low or falling product revenue, with revenue still reliant on grants and contracts, would show the shift has not yet produced enough product sales.
